Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
- PMID: 7923663
- DOI: 10.1161/01.cir.90.4.1786
Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
Abstract
Background: During the past half-century, the ECG has been used extensively for the diagnosis of left ventricular hypertrophy. Persons with ECG evidence of left ventricular hypertrophy are at increased risk for the development of cardiovascular disease.
Methods and results: Subjects from the Framingham Heart Study with ECG evidence of left ventricular hypertrophy were eligible for this investigation if they were free of cardiovascular disease and did not have complete bundle-branch block or Wolff-Parkinson-White syndrome. Logistic regression analyses of pooled biennial examinations were used to determine risk for cardiovascular disease as a function of baseline voltage (sum of R wave in aVL plus S wave in V3) and repolarization and as a function of serial changes in these ECG features of hypertrophy. The eligible sample consisted of 274 men (mean age, 60 years) and 250 women (mean age, 64 years) who contributed 2660 person-examinations. During follow-up, there were 269 new cardiovascular events. Compared with subjects in the first quartile of voltage at baseline, the age-adjusted odds ratio for cardiovascular disease among subjects in the fourth quartile was 3.08 (95% confidence interval [CI], 1.87 to 5.07) in men and 3.29 (95% CI, 1.78 to 6.09) in women. Compared with a normal repolarization pattern, the presence of severe repolarization abnormalities was associated with an age-adjusted odds ratio of 5.84 (95% CI, 3.55 to 9.62) in men and 2.47 (95% CI, 1.38 to 4.42) in women. Subjects with a serial decline in voltage were at lower risk for cardiovascular disease than were those with no serial change (men: odds ratio after adjusting for age and baseline voltage, 0.46; 95% CI, 0.26 to 0.84; women: odds ratio, 0.56; 95% CI, 0.30 to 1.04). In contrast, those with a serial increase in voltage were at greater risk for cardiovascular disease (men: odds ratio, 1.86; 95% CI, 1.14 to 3.03; women: odds ratio, 1.61; 95% CI, 0.91 to 2.84). Compared with those with no serial change, an improvement in repolarization was associated with a marginally significant reduction in cardiovascular risk in men (odds ratio after adjusting for age and baseline repolarization, 0.45; 95% CI, 0.20 to 1.01). Worsening of repolarization was associated with increased risk for cardiovascular disease in both sexes (men: odds ratio, 1.89; 95% CI, 1.05 to 3.40; women: odds ratio, 2.02; 95% CI, 1.07 to 3.81).
Conclusions: The results of this investigation suggest that regression of ECG features of left ventricular hypertrophy confers an improvement in risk for cardiovascular disease, whereas serial worsening imposes increased risk. The benefits to be derived from regression of left ventricular hypertrophy must be confirmed in other clinical settings.
Similar articles
-
The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy.J Hypertens. 2009 Aug;27(8):1697-704. doi: 10.1097/HJH.0b013e32832c0031. J Hypertens. 2009. PMID: 19424088
-
Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study.Am J Hypertens. 2007 Sep;20(9):997-1004. doi: 10.1016/j.amjhyper.2007.04.003. Am J Hypertens. 2007. PMID: 17765142
-
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.JAMA. 2004 Nov 17;292(19):2343-9. doi: 10.1001/jama.292.19.2343. JAMA. 2004. PMID: 15547161 Clinical Trial.
-
Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.J Electrocardiol. 2014 Sep-Oct;47(5):630-5. doi: 10.1016/j.jelectrocard.2014.07.003. Epub 2014 Jul 3. J Electrocardiol. 2014. PMID: 25052475 Review.
-
Electrocardiographic left ventricular hypertrophy and the risk of adverse cardiovascular events: a critical appraisal.J Electrocardiol. 2014 Sep-Oct;47(5):649-54. doi: 10.1016/j.jelectrocard.2014.06.002. Epub 2014 Jun 9. J Electrocardiol. 2014. PMID: 25012077 Review.
Cited by
-
Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy.Br J Pharmacol. 2013 Apr;168(8):1794-807. doi: 10.1111/bph.12066. Br J Pharmacol. 2013. PMID: 23176298 Free PMC article.
-
Do Combined Electrocardiographic and Echocardiographic Markers of Left Ventricular Hypertrophy Improve Cardiovascular Risk Estimation?J Clin Hypertens (Greenwich). 2016 Sep;18(9):846-54. doi: 10.1111/jch.12834. Epub 2016 May 10. J Clin Hypertens (Greenwich). 2016. PMID: 27160298 Free PMC article.
-
Red cell distribution width and end-organ damage in patients with systo-diastolic hypertension.Arch Med Sci. 2016 Apr 1;12(2):319-25. doi: 10.5114/aoms.2016.59257. Epub 2016 Apr 12. Arch Med Sci. 2016. PMID: 27186175 Free PMC article.
-
Regression of the Left Ventricular Hypertrophy in Patients with Essential Hypertension on Standard Drug Therapy.Discoveries (Craiova). 2020 Sep 30;8(3):e115. doi: 10.15190/d.2020.12. Discoveries (Craiova). 2020. PMID: 33102689 Free PMC article.
-
Is left ventricular hypertrophy regression important? Does the tool used to detect it matter?J Clin Hypertens (Greenwich). 2009 Aug;11(8):441-7. doi: 10.1111/j.1751-7176.2009.00137.x. J Clin Hypertens (Greenwich). 2009. PMID: 19695032 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous